Central Nervous System Lymphoma Pipeline Insight
DelveInsight’s, “Central Nervous System Lymphoma – Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Central Nervous System Lymphoma Understanding
Central Nervous System Lymphoma: Overview
Central nervous system lymphoma is a rare non-Hodgkin lymphoma in which malignant (cancer) cells from lymph tissue form in the brain and/or spinal cord (primary CNS) or spread from other parts of the body to the brain and/or spinal cord (secondary CNS). Central nervous system lymphoma is more common in men than women. the exact causes of CNS lymphoma are not known, there are several factors that may increase a person's risk for developing the disease, such as having a compromised immune system due to acquired immunodeficiency syndrome (AIDS), other disorders of the immune system, or chronic immunosuppression (a reduced function of the immune system) as a result of organ transplantation. To diagnose Central Nervous System lymphoma different tests are used to examine the eyes, brain and spinal cord. Physical exam and history, neurological exam to check mental status, coordination, ability to walk normally and how well the muscles, senses and reflexes work, slit-lamp eye exam - this test uses a special microscope with a bright, narrow slit of light to check the outside and inside of the eye. Vitrectomy - A surgical procedure in which some of the vitreous humor (the gel-like fluid inside the eyeball) is removed and examined under a microscope to check for cancer cells. Chest x-ray and CT scans of the chest and abdomen. MRI scans of the brain and spinal cord. There is no standard treatment for Central Nervous System lymphoma. Methotrexate-based combinations that include rituximab (Rituxan) have been the most successful for Central Nervous System lymphoma patients. Methotrexate is usually given at high doses and require that the patient be hospitalized while giving the chemotherapy.
"Central Nervous System Lymphoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Central Nervous System Lymphoma pipeline landscape is provided which includes the disease overview and Central Nervous System Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Central Nervous System Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Central Nervous System Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Central Nervous System Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Central Nervous System Lymphoma.
Central Nervous System Lymphoma Emerging Drugs Chapters
This segment of the Central Nervous System Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Central Nervous System Lymphoma Emerging Drugs
F520: Shandong New Time Pharmaceutical
F 520 is a humanized monoclonal antibody targeting programmed cell death 1 receptor antagonists being developed by Shandong New Time Pharmaceutical. The drug is being investigated in Phase II stage of development for the treatment of patients with Primary and secondary Central Nervous System Lymphoma.
Tirabrutinib: Ono Pharmaceuticals
Velexbru, discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Ono Pharmaceutical has initiated a Phase II clinical trial in US with Velexbru in patients with primary central nervous system lymphoma.
Further product details are provided in the report……..
Central Nervous System Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Central Nervous System Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Central Nervous System Lymphoma
There are approx. 13+ key companies which are developing the therapies for Central Nervous System Lymphoma. The companies which have their Central Nervous System Lymphoma drug candidates in the most advanced stage, i.e. Phase II include, Shandong New Time Pharmaceutical.
DelveInsight’s report covers around 13+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Central Nervous System Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Central Nervous System Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Central Nervous System Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Central Nervous System Lymphoma drugs.
Central Nervous System Lymphoma Report Insights
- Central Nervous System Lymphoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Central Nervous System Lymphoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Central Nervous System Lymphoma drugs?
- How many Central Nervous System Lymphoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Central Nervous System Lymphoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Central Nervous System Lymphoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Central Nervous System Lymphoma and their status?
- What are the key designations that have been granted to the emerging drugs?